{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:59:04Z","timestamp":1789142344928,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7202216"],"award-info":[{"award-number":["7202216"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970698"],"award-info":[{"award-number":["81970698"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970708"],"award-info":[{"award-number":["81970708"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.phrs.2024.107157","type":"journal-article","created":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T19:46:04Z","timestamp":1711309564000},"page":"107157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The opportunities and challenges of the disease-modifying immunotherapy for type 1 diabetes: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"203","author":[{"given":"Chu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suiyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.phrs.2024.107157_bib1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40618-017-0641-y","article-title":"Immunotherapy for type 1 diabetes","volume":"40","author":"Frumento","year":"2017","journal-title":"J. Endocrinol. Invest."},{"issue":"6554","key":"10.1016\/j.phrs.2024.107157_bib2","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1126\/science.abh1654","article-title":"Immunotherapy: building a bridge to a cure for type 1 diabetes","volume":"373","author":"Bluestone","year":"2021","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.phrs.2024.107157_bib3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cmet.2019.11.017","article-title":"New frontiers in the treatment of type 1 diabetes","volume":"31","author":"Warshauer","year":"2020","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.phrs.2024.107157_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MED.0000000000000547","article-title":"Endotypes in T1D: B lymphocytes and early onset","volume":"27","author":"Smith","year":"2020","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"8499","key":"10.1016\/j.phrs.2024.107157_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(86)91943-4","article-title":"Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial","volume":"2","author":"Feutren","year":"1986","journal-title":"Lancet"},{"issue":"9789","key":"10.1016\/j.phrs.2024.107157_bib6","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","article-title":"Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"378","author":"Orban","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.phrs.2024.107157_bib7","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2337\/dc13-0604","article-title":"Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment","volume":"37","author":"Orban","year":"2014","journal-title":"Diabetes Care"},{"issue":"22","key":"10.1016\/j.phrs.2024.107157_bib8","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"346","author":"Herold","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.phrs.2024.107157_bib9","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.2337\/db13-0345","article-title":"Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders","volume":"62","author":"Herold","year":"2013","journal-title":"Diabetes"},{"issue":"9790","key":"10.1016\/j.phrs.2024.107157_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(11)60931-8","article-title":"Prot\u00e9g\u00e9 Trial Investigators. Teplizumab for treatment of type 1 diabetes (Prot\u00e9g\u00e9 study): 1-year results from a randomised, placebo-controlled trial","volume":"378","author":"Sherry","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.phrs.2024.107157_bib11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00125-012-2753-4","article-title":"Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial","volume":"56","author":"Herold","year":"2013","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.phrs.2024.107157_bib12","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.clim.2009.04.007","article-title":"Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years","volume":"132","author":"Herold","year":"2009","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.phrs.2024.107157_bib13","doi-asserted-by":"crossref","unstructured":"K.C. Herold, B.N. Bundy, S.A. Long, J.A. Bluestone, L.A. DiMeglio, M.J. Dufort, S.E. Gitelman, P.A. Gottlieb, J.P. Krischer, P.S. Linsley, J.B. Marks, W. Moore, A. Moran, H. Rodriguez, W.E. Russell, D. Schatz, J.S. Skyler, E. Tsalikian, D.K. Wherrett, A.G. Ziegler, C.J. GreenbaumType 1 Diabetes TrialNet Study Group. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056\/NEJMoa1902226. Epub 2019 Jun 9. Erratum in: N Engl J Med. Feb 6;382(6):586.2020.","DOI":"10.1056\/NEJMoa1902226"},{"key":"10.1016\/j.phrs.2024.107157_bib14","first-page":"18","article-title":"FDA approves teplizumab: a milestone in type 1 diabetes","volume":"11","author":"Hirsch","year":"2023"},{"issue":"25","key":"10.1016\/j.phrs.2024.107157_bib15","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMoa043980","article-title":"Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes","volume":"352","author":"Keymeulen","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2024.107157_bib16","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00125-009-1644-9","article-title":"Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass","volume":"53","author":"Keymeulen","year":"2010","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.phrs.2024.107157_bib17","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.2337\/dc13-0327","article-title":"Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes","volume":"37","author":"Aronson","year":"2014","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.phrs.2024.107157_bib18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/dme.12361","article-title":"Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study","volume":"31","author":"Ambery","year":"2014","journal-title":"Diabet. Med."},{"issue":"2","key":"10.1016\/j.phrs.2024.107157_bib19","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00125-020-05317-y","article-title":"A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes","volume":"64","author":"Keymeulen","year":"2021","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.phrs.2024.107157_bib20","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2337\/dc18-0494","article-title":"Type 1 diabetes TrialNet ATG-GCSF Study Group. Low-dose anti-thymocyte globulin (ATG) preserves \u03b2-cell function and improves HbA1c in new-onset type 1 diabetes","volume":"41","author":"Haller","year":"2018","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.phrs.2024.107157_bib21","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2337\/db19-0057","article-title":"Type 1 diabetes TrialNet ATG-GCSF Study Group. Low-dose anti-thymocyte globulin preserves C-peptide, reduces HbA1c, and increases regulatory to conventional T-cell ratios in new-onset type 1 diabetes: two-year clinical trial data","volume":"68","author":"Haller","year":"2019","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.phrs.2024.107157_bib22","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1172\/JCI78492","article-title":"Anti-thymocyte globulin\/G-CSF treatment preserves \u03b2 cell function in patients with established type 1 diabetes","volume":"125","author":"Haller","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.phrs.2024.107157_bib23","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-8587(13)70065-2","article-title":"Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial","volume":"1","author":"Gitelman","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"10.1016\/j.phrs.2024.107157_bib24","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00125-016-3917-4","article-title":"Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial","volume":"59","author":"Gitelman","year":"2016","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.phrs.2024.107157_bib25","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1172\/JCI81722","article-title":"Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients","volume":"125","author":"Rigby","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"22","key":"10.1016\/j.phrs.2024.107157_bib26","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"9881","key":"10.1016\/j.phrs.2024.107157_bib27","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(13)60023-9","article-title":"Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials","volume":"381","author":"Moran","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.phrs.2024.107157_bib28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.diabet.2016.08.005","article-title":"Interleukin-1 antagonism in type 1 diabetes of long duration","volume":"42","author":"Seelig","year":"2016","journal-title":"Diabetes Metab."},{"issue":"7","key":"10.1016\/j.phrs.2024.107157_bib29","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2337\/dc09-0054","article-title":"Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study","volume":"32","author":"Mastrandrea","year":"2009","journal-title":"Diabetes Care"},{"issue":"21","key":"10.1016\/j.phrs.2024.107157_bib30","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1056\/NEJMoa2006136","article-title":"Golimumab and beta-cell function in youth with new-onset type 1 diabetes","volume":"383","author":"Quattrin","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2024.107157_bib31","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2337\/db14-0443","article-title":"CXCR1\/2 inhibition blocks and reverses type 1 diabetes in mice","volume":"64","author":"Citro","year":"2015","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.phrs.2024.107157_bib32","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1111\/dom.14770","article-title":"Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: a multicentre, randomized, double-blind, placebo-controlled trial","volume":"24","author":"Piemonti","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2024.107157_bib33","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/pedi.13162","article-title":"Human plasma-derived alpha1 -proteinase inhibitor in patients with new-onset type 1 diabetes mellitus: a randomized, placebo-controlled proof-of-concept study","volume":"22","author":"Lagarde","year":"2021","journal-title":"Pediatr. Diabetes"},{"issue":"23","key":"10.1016\/j.phrs.2024.107157_bib34","doi-asserted-by":"crossref","first-page":"6032","DOI":"10.3390\/ijms20236032","article-title":"A phase II, double-blind, randomized, placebo-controlled, multicenter study evaluating the efficacy and safety of alpha-1 antitrypsin (AAT) (Glassia\u00ae) in the treatment of recent-onset type 1 diabetes","volume":"20","author":"Lebenthal","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.phrs.2024.107157_bib35","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2306691","article-title":"BANDIT Study Group. Baricitinib and \u03b2-cell function in patients with new-onset type 1 diabetes","volume":"389","author":"Waibel","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2024.107157_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00125-023-06014-2","article-title":"AG019-T1D-101 Trial Investigators. A first-in-human, open-label phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab","volume":"67","author":"Mathieu","year":"2024","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.phrs.2024.107157_bib37","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1107096","article-title":"GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus","volume":"366","author":"Ludvigsson","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9788","key":"10.1016\/j.phrs.2024.107157_bib38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(11)60895-7","article-title":"Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial","volume":"378","author":"Wherrett","year":"2011","journal-title":"Lancet"},{"issue":"9229","key":"10.1016\/j.phrs.2024.107157_bib39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(00)02579-4","article-title":"Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diab\u00e8te Insuline Orale group","volume":"356","author":"Chaillous","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.phrs.2024.107157_bib40","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2337\/db10-1360","article-title":"Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes","volume":"60","author":"Fourlanos","year":"2011","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.phrs.2024.107157_bib41","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/dc09-0449","article-title":"NBI-6024 Study Group. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes","volume":"32","author":"Walter","year":"2009","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.phrs.2024.107157_bib42","first-page":"915","article-title":"Trial Outcome Markers Initiative collaboration. C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis. Lancet","volume":"11","author":"Taylor","year":"2023","journal-title":"Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107157_bib43","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41574-020-00443-4","article-title":"Type 1 diabetes mellitus as a disease of the \u03b2-cell (do not blame the immune system?)","volume":"17","author":"Roep","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"issue":"20","key":"10.1016\/j.phrs.2024.107157_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aao4013","article-title":"ImMaDiab Study Group. Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors","volume":"3","author":"Culina","year":"2018","journal-title":"Sci. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107157_bib45","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ajpath.2016.11.002","article-title":"Demonstration of tissue resident memory CD8 T cells in insulitic lesions in adult patients with recent-onset type 1 diabetes","volume":"187","author":"Kuric","year":"2017","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107157_bib46","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0889-8529(01)00020-2","article-title":"Cytokine and immunosuppressive therapies of type 1 diabetes mellitus","volume":"31","author":"Gottlieb","year":"2002","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"2","key":"10.1016\/j.phrs.2024.107157_bib47","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2249.1991.tb05806.x","article-title":"Cytokines in sera from insulin-dependent diabetic patients at diagnosis","volume":"86","author":"Cavallo","year":"1991","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107157_bib48","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1530\/EJE-06-0693","article-title":"Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis","volume":"156","author":"van Eijk","year":"2007","journal-title":"Eur. J. Endocrinol."},{"issue":"9","key":"10.1016\/j.phrs.2024.107157_bib49","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2362.2004.01390.x","article-title":"Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab","volume":"34","author":"Yazdani-Biuki","year":"2004","journal-title":"Eur. J. Clin. Invest."},{"issue":"7716","key":"10.1016\/j.phrs.2024.107157_bib50","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-018-0341-6","article-title":"Pancreatic islets communicate with lymphoid tissues via exocytosis of insulin peptides","volume":"560","author":"Wan","year":"2018","journal-title":"Nature"},{"issue":"48","key":"10.1016\/j.phrs.2024.107157_bib51","doi-asserted-by":"crossref","first-page":"E10418","DOI":"10.1073\/pnas.1713543114","article-title":"Resident macrophages of pancreatic islets have a seminal role in the initiation of autoimmune diabetes of NOD mice","volume":"114","author":"Carrero","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.phrs.2024.107157_bib52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11892-017-0915-y","article-title":"Deciphering the pathogenesis of human Type 1 Diabetes (T1D) by interrogating T cells from the \"Scene of the Crime","volume":"17","author":"Kent","year":"2017","journal-title":"Curr. Diab Rep."},{"issue":"2","key":"10.1016\/j.phrs.2024.107157_bib53","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2217\/imt.14.104","article-title":"Impact of disease heterogeneity on treatment efficacy of immunotherapy in Type 1 diabetes: different shades of gray","volume":"7","author":"Woittiez","year":"2015","journal-title":"Immunotherapy"},{"issue":"10","key":"10.1016\/j.phrs.2024.107157_bib54","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.2337\/dc15-1429","article-title":"Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report","volume":"38","author":"Wherrett","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.phrs.2024.107157_bib55","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/dme.13153","article-title":"\u03b2-cell specific T-lymphocyte response has a distinct inflammatory phenotype in children with Type 1 diabetes compared with adults","volume":"34","author":"Arif","year":"2017","journal-title":"Diabet. Med."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824001014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824001014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:57:17Z","timestamp":1778518637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824001014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":55,"alternative-id":["S1043661824001014"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107157","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The opportunities and challenges of the disease-modifying immunotherapy for type 1 diabetes: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107157","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107157"}}